EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Can Alpha-Glucosidase Activity in Plasma or Leukocytes Serve as a Biomarker for Future Gene Therapy in Classic Infantile Pompe Disease?

Martha C Faraguna, Daniël A M Lambregts, Ina Barzel, Ed H Jacobs, Marianne Hoogeveen-Westerveld, Nadine A M E van der Beek, W W M Pim Pijnappel, Serena Gasperini, Tim Preijers, Johanna M P van den Hout, Ans T van der Ploeg

BioDrugs · 2026

DOI: 10.1007/s40259-025-00757-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BioDrugs, 2026. Verfasst von Martha C Faraguna und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Center for Lysosomal and Metabolic Diseases, Erasmus MC University Medical Center, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Glycogen Storage Disease Type II, alpha-Glucosidases, Leukocytes, Genetic Therapy. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Health Holland TKI subsidy.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We studied alpha-glucosidase activity in plasma and leukocytes after an infusion of 40 mg/kg of recombinant alglucosidase alpha in patients with classic infantile Pompe disease to assess the pharmacokinetics and identify potential surrogate efficacy markers of gene therapy in patients on enzyme replacement therapy. Samples were collected by pharmacokinetic curves (n = 5) and random samples (n = 21 patients). Alpha-glucosidase activity was measured in plasma (substrate 4-methylumbelliferyl-α-D-glucopyranoside, MU) and leukocytes (substrate glycogen, Gn, and MU). Plasma peak concentration occurred at the end of the infusion, reaching concentrations > 5000 and > 100,000 times higher than the control and untreated patient levels, with a median half-life of 3.1 h (1.3-4.2 h). In leukocytes, plasma peak concentration occurred 24 h after the start of enzyme replacement therapy; plasma peak concentration did not exceed the control level (0.7 [Gn] and 0.9 [MU] times higher than controls). The estimated half-life was 2-4 days. Seven days after enzyme replacement therapy, median enzyme activity was 1.3 times higher than the control levels in plasma and within the control range in leukocytes; after 14 days, median values in plasma and leukocytes were below the control level. These findings suggest alpha-glucosidase activity in plasma and leukocytes may serve as an efficacy marker for gene therapy studies in patients with classic infantile Pompe disease receiving enzyme replacement therapy. Similar studies with next-generation enzyme replacement therapy are advised.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glycogen Storage Disease Type IIalpha-GlucosidasesLeukocytesGenetic TherapyHumansBiomarkersEnzyme Replacement TherapyInfantMaleFemaleChild, PreschoolHalf-LifeRecombinant Proteins

Substanzen

alpha-GlucosidasesBiomarkersRecombinant ProteinsGAA protein, human

Autor:innen und Institutionen

  • Department of Pediatrics, Center for Lysosomal and Metabolic Diseases, Erasmus MC University Medical Center, Rotterdam, The Netherlands.
  • School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
  • Pediatrics, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.
  • Department of Hospital Pharmacy, Erasmus MC, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands.
  • Center for Lysosomal and Metabolic Diseases, Erasmus MC University Medical Center, Rotterdam, The Netherlands.
  • Department of Clinical Genetics, Erasmus MC University Medical Center, Rotterdam, The Netherlands.

Förderung

  • Health Holland TKI subsidy

Zitieren

APA

Faraguna, M. C., Lambregts, D. A. M., Barzel, I., Jacobs, E. H., Hoogeveen-Westerveld, M., van der Beek, N. A. M. E., Pijnappel, W. W. M. P., Gasperini, S., Preijers, T., van den Hout, J. M. P., & van der Ploeg, A. T. (2026). Can Alpha-Glucosidase Activity in Plasma or Leukocytes Serve as a Biomarker for Future Gene Therapy in Classic Infantile Pompe Disease?. BioDrugs. https://doi.org/10.1007/s40259-025-00757-7

Vancouver

Faraguna MC, Lambregts DAM, Barzel I, Jacobs EH, Hoogeveen-Westerveld M, van der Beek NAME, et al. Can Alpha-Glucosidase Activity in Plasma or Leukocytes Serve as a Biomarker for Future Gene Therapy in Classic Infantile Pompe Disease?. BioDrugs. 2026. doi:10.1007/s40259-025-00757-7

BibTeX
@article{Faraguna2026,
  author = {Faraguna, Martha C and Lambregts, Daniël A M and Barzel, Ina and Jacobs, Ed H and Hoogeveen-Westerveld, Marianne and van der Beek, Nadine A M E and Pijnappel, W W M Pim and Gasperini, Serena and Preijers, Tim and van den Hout, Johanna M P and van der Ploeg, Ans T},
  title = {Can Alpha-Glucosidase Activity in Plasma or Leukocytes Serve as a Biomarker for Future Gene Therapy in Classic Infantile Pompe Disease?},
  journal = {BioDrugs},
  year = {2026},
  doi = {10.1007/s40259-025-00757-7}
}
Kostenlos starten →